Avantor, Inc. 2022 Form 10-K Summary
Business Context and Reporting Period
Avantor is a global manufacturer, distributor, and service provider serving biopharmaceutical, healthcare, education and government, and advanced technologies and applied materials customers. It reported three geographic segments: Americas, Europe, and AMEA. This filing covers the fiscal year ended December 31, 2022. Although the request references 2022 Q4, the provided filing is an annual Form 10-K and does not present a separate fourth-quarter income statement or cash flow statement.
Avantor served more than 300,000 customer locations in over 180 countries, with more than 85% of net sales described as recurring in nature. No single end customer represented more than 5% of net sales.
Financial Performance and Key Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Net sales | $7,512.4 million | $7,386.1 million | +$126.3 million; +1.7% |
| Gross profit | $2,602.8 million | $2,502.7 million | +$100.1 million |
| Gross margin | 34.6% | 33.9% | +70 basis points |
| Operating income | $1,130.2 million | $972.2 million | +$158.0 million |
| Net income | $686.5 million | $572.6 million | +$113.9 million |
| Net income available to common stockholders | $662.3 million | $508.0 million | +$154.3 million |
| Diluted EPS | $1.01 | $0.85 | +$0.16 |
| Adjusted EBITDA | $1,570.7 million | $1,458.6 million | +$112.1 million; +7.7% |
| Adjusted EBITDA margin | 20.9% | 19.8% | +110 basis points |
| Cash flow from operations | $843.6 million | $953.6 million | -$110.0 million |
| Free cash flow | $710.2 million | $920.3 million | -$210.1 million |
Net sales growth included 2.4% organic growth, a $268.2 million favorable contribution from acquisitions, and a $317.1 million unfavorable foreign-currency impact. Organic growth was 6.0% excluding COVID-19-related sales effects.
- Americas net sales increased 5.5% to $4,471.2 million; Adjusted EBITDA increased 10.1% to $1,077.3 million.
- Europe net sales decreased 6.0% to $2,516.5 million, primarily due to currency translation; Adjusted EBITDA decreased 2.7% to $524.1 million.
- AMEA net sales increased 11.3% to $524.7 million; Adjusted EBITDA increased 24.2% to $141.5 million.
Operating income benefited from higher gross profit, the absence of significant 2021 acquisition costs, and lower incentive compensation expense. These benefits were partly offset by higher amortization, inflation, and workforce investments. Interest expense increased to $265.8 million from $217.4 million, reflecting incremental acquisition-related debt and higher interest rates. Income tax expense declined to $164.6 million from $180.4 million, helped by favorable resolution of uncertain tax positions and lower effective tax rates in Europe.
Liquidity, Cash Flow, Debt, and Capital Structure
- Cash and cash equivalents were $372.9 million at December 31, 2022, compared with $301.7 million at December 31, 2021.
- Total reported liquidity was $904.7 million, consisting of cash and cash equivalents plus $531.8 million of unused credit-facility availability.
- Total debt was $6,287.5 million net of deferred financing costs, compared with $7,023.2 million at year-end 2021. Gross debt was $6,349.1 million.
- 2022 debt repayments totaled $947.0 million, while debt borrowings totaled $327.2 million. The company made substantial optional repayments on its Euro and U.S. dollar term loans.
- Debt principal payments scheduled for 2023 totaled $364.2 million; total contractual debt principal payments were $6,349.1 million.
- The company had $2,794.2 million of borrowings under credit facilities at year-end, generally at variable interest rates. A 100-basis-point increase in applicable variable rates, including the interest-rate swap, was estimated to increase annual interest expense by $20.4 million.
- Avantor amended its receivables facility, increasing the funding limit to $400.0 million and extending its maturity to October 2025. The revolving credit facility had $515.0 million of unused capacity.
- Operating cash flow declined because of higher interest and tax payments, incentive compensation, and customer prebate payments. Capital expenditures increased to $133.4 million from $111.1 million, mainly for global supply-chain expansion.
- In May 2022, all outstanding mandatory convertible preferred stock converted into 62.9 million common shares. No preferred shares remained outstanding at year-end, and the final preferred dividend payment was $32.4 million.
Material Changes Versus the Prior Comparable Period
- Revenue grew modestly despite a $317.1 million currency headwind and declining COVID-19-related demand, particularly for diagnostic testing, vaccines, and PPE offerings.
- Margins expanded: gross margin increased 70 basis points and Adjusted EBITDA margin increased 110 basis points, driven by commercial excellence, proprietary-product growth, and favorable product mix.
- Cash generation weakened: operating cash flow declined 11.5% and free cash flow declined 22.8%.
- Debt decreased by approximately $735.7 million net of deferred financing costs, reflecting term-loan repayments.
- Foreign currency translation reduced reported results and contributed to a $57.1 million decline in other comprehensive income.
- Goodwill increased to $5,652.6 million, while other intangible assets declined to $4,133.3 million. Combined goodwill and intangible assets represented 73% of total assets.
- The company recorded no goodwill impairment in its October 2022 testing. However, lower-than-expected Ritter revenue triggered heightened long-lived-asset impairment risk.
Outlook, Commentary, Risks, and Unusual Items
Management did not provide quantified forward guidance in the supplied filing. Management emphasized continued investment in proprietary products, customer workflow integration, emerging areas such as cell and gene therapy, digital channels, operational efficiency, and selective acquisitions.
- Ritter risk: Ritter revenue declined due primarily to reduced demand for medical fluid-handling tips following lower COVID-19 testing. Ritter’s net assets excluding goodwill had a carrying value of $247.0 million at year-end, including $164.7 million of finite-lived intangible assets and $129.2 million of property, plant, and equipment. Further underperformance could require an impairment charge.
- Supply chain and inflation: Sourcing constraints, freight costs, and inflation affected operating costs and may continue to pressure margins.
- COVID-19 normalization: Demand for COVID-related products declined, while the pandemic continued to create potential operational, workforce, customer-demand, and supply-chain uncertainty.
- Leverage and interest rates: Significant debt, variable-rate borrowings, restrictive covenants, and substantial scheduled maturities expose the company to refinancing, liquidity, and interest-rate risk.
- Foreign exchange: A 10% strengthening of the U.S. dollar against other currencies would have reduced 2022 net income by an estimated $14.3 million and Adjusted EBITDA by $60.3 million.
- Goodwill and intangible assets: The company relies on forecasts, discount rates, and market multiples in impairment testing. Adverse changes in operating performance or valuation assumptions could result in material charges.
- Regulatory and environmental exposure: Operations are subject to extensive product, chemical, environmental, health, safety, export-control, data-protection, and cGMP requirements. Known environmental liabilities included $2.6 million related to groundwater remediation in New Jersey and $1.0 million related to a site in Poland.
- Legal contingencies: The filing states that no outstanding litigation was expected to result in material losses if decided against the company and no unasserted matters were believed reasonably possible to result in a material loss.
- Dividends: Avantor stated that it does not currently expect to pay common-stock dividends, and debt agreements restrict certain distributions.
Most Important Facts for Investors to Verify
- Reconcile consolidated revenue growth with organic growth, acquisition effects, currency translation, and the decline in COVID-19-related demand.
- Assess whether gross-margin and Adjusted EBITDA-margin expansion is sustainable after inflation, freight, and mix effects normalize.
- Review debt maturities, variable-rate exposure, covenant requirements, hedging arrangements, and the company’s ability to continue debt reduction.
- Monitor Ritter’s revenue recovery and test whether its carrying value remains recoverable.
- Evaluate the concentration of goodwill and intangible assets relative to total assets and sensitivity to impairment assumptions.
- Confirm the conversion of all mandatory convertible preferred stock and its effect on share count, preferred dividends, and diluted EPS.
- Review cash conversion, working-capital requirements, capital expenditures, and the large portion of cash held by non-U.S. subsidiaries.
- Read the audited financial statements and notes for detailed debt terms, environmental obligations, tax reserves, derivatives, and commitments.